Human Oncology & Pathogenesis Program
The Michael Berger Lab
Research

The focus of the Berger laboratory is to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response.

Featured News
Publications
People

Michael F. Berger, PhD
Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
- Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
- PhD, Harvard University
- [email protected]
- Email Address
- 646-888-3386
- Office Phone
- View physician profile
- Physician profile
Members










Senior Computational Biologist
Senior Research Assistant, CMO Technology Innovation
Fellow
Senior Computational Biologist, CMO Technology Innovation

WGS Graduate Student

Research Fellow

Bioinformatics Software Engineer, cfDNA Informatics

Computational Biologist, CMO Technology Innovation

Bioinformatics Engineer, CMO Technology Innovation

Manager, CMO Technology Innovation

Research Lab Manager, CMO Technology Innovation
Assistant Attending
Senior Computational Biologist, cfDNA Informatics
Bioinformatics Tech

Assistant Attending

Principal Computational Biologist, cfDNA Informatics

Senior Computational Biologist

Senior Research Assistant, CMO Technology Innovation
Research Assistant, CMO Technology Innovation











Lab Alumni

Research Fellow

Medical Student

Research Technician

Senior Project Manager

Research Fellow

Lab Manager, CMO Technology Innovation

Computational Biologist, CMO Technology Innovation

Research Fellow

Graduate Research Assistant

Computational Biologist, CMO Technology Innovation

Bioinformatics Tech

Graduate Student

Group Leader, Innovation Laboratory

Computational Biologist

Clinical Research Fellow

Bioinformatics Technician
Open Positions
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael F. Berger discloses the following relationships and financial interests:
-
Advances in Genome Biology and Technology (AGBT)
Provision of Services (uncompensated) -
American Association for Cancer Research
Provision of Services (uncompensated) -
American Society of Clinical Oncology (ASCO)
Provision of Services -
Cold Spring Harbor Laboratory
Provision of Services (uncompensated) -
Cycle for Survival
Provision of Services (uncompensated) -
European Molecular Biology Laboratory
Provision of Services (uncompensated) -
European Society for Medical Oncology (ESMO)
Provision of Services (uncompensated)
-
Fox Chase Cancer Center
Provision of Services -
Hospital Sirio-Libanes
Provision of Services -
JCO Precision Oncology
Provision of Services (uncompensated) -
Journal of Molecular Diagnostics
Provision of Services (uncompensated) -
Journal of Visualized Experiments
Provision of Services (uncompensated) -
Qiagen
Provision of Services (uncompensated) -
Stand Up to Cancer
Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].